A virtual disruptive late clinical-stage novel ophthalmology drug platform

Theialife is aiming to reduce myopic progression in children & build a portfolio of innovative ophthalmic range for vision threatening complications. Bringing the “discovery” back to “drug-discovery” in ophthalmology.

Because every eye deserves sight.

For the future of every childs vision.

Lead Product Candidates

Our late-stage phase 3 drug – 7MX – provides unique therapeutic options for millions of diagnosed but untreated or undertreated myopia in children.

Are you a Healthcare Practitioner ?

Learn more about myopia & how to treat it.

Meet us at

Theialife is featured on the front cover of the coveted British Journal of Ophthalmology

To learn more about the groundbreaking benefits of 7-Methyl-Xanthine in the use of Myopia control and treatment in children, The British journal of Ophthalmology published a peer-reviewed article.

August 18, 2022

Read more

Theialife is featured in the International Journal of Ophthalmology

Featured in a second peer-reviewed publication in the International Journal of Ophthalmology. Read our latest article on the “Role of 7-methylxanthine in myopia prevention and control: a mini-review”

January 31, 2023